Articles from Pelage Pharmaceuticals

Pelage Pharmaceuticals, a clinical-stage regenerative medicine biotechnology company, today announced that its first-in-class approach for treating hair loss with investigational medicine PP405 will be featured in a presentation about advances in the hair loss treatment landscape and regenerative mechanisms on Saturday, March 28th at the American Academy of Dermatology (AAD) Annual Meeting, taking place in Denver, Colorado.

Pelage Pharmaceuticals, a clinical-stage regenerative medicine biotechnology company, today announced the appointment of Maykin Ho, Ph.D., to its board of directors, and the promotions of Nathan Wheeler to Chief Operating Officer and Lisa Sherman to Vice President, Head of Clinical Operations.

Pelage Pharmaceuticals, a clinical-stage regenerative medicine biotechnology company, today announced the close of a $120 million Series B financing co-led by ARCH Venture Partners and GV (Google Ventures), with participation from existing investors including Main Street Advisors, Visionary Ventures, and YK Bioventures. The financing will support the continued advancement of Pelage’s lead program, PP405, a topical small molecule designed to reactivate dormant hair follicle stem cells, offering a potential first-in-class approach for both men and women experiencing hair loss.

Pelage Pharmaceuticals, a clinical-stage regenerative medicine company, today announced positive results from its Phase 2a clinical trial of PP405 — a topical therapy for androgenetic alopecia advancing through the FDA clinical development pathway. PP405 is designed to reactivate dormant hair follicle stem cells, offering a potential first-in-class approach for both men and women experiencing hair loss.